For a patient with major depressive disorder, generalized anxiety disorder, post‑traumatic stress disorder, and borderline personality disorder who overdosed on Vyvanse (lisdexamfetamine), cyclobenzaprine, and clonazepam, received haloperidol and lorazepam in the emergency department for agitation, and now reports two weeks of reduced sleep, helplessness, hopelessness, recent panic attacks, and relationship stress, what medication regimen should be started during inpatient admission?

Inpatient Medication Management Following Overdose and Acute Agitation

Start an SSRI (sertraline 50 mg daily or escitalopram 10 mg daily) as first-line treatment for this patient's major depressive disorder, PTSD, anxiety, and panic symptoms, while avoiding reinitiation of benzodiazepines given the overdose history and borderline personality disorder diagnosis. 1, 2, 3

Rationale for SSRI Monotherapy

The patient presents with a complex psychiatric picture requiring careful medication selection. Given the recent overdose involving clonazepam (a benzodiazepine), the acute agitation already managed with haloperidol and lorazepam in the ED, and the underlying diagnoses, the treatment approach must prioritize safety while addressing the core depressive and anxiety symptoms.

SSRIs are the evidence-based first-line pharmacotherapy for major depressive disorder 1, with moderate-quality evidence supporting their efficacy. The American College of Physicians guidelines specifically recommend second-generation antidepressants as initial treatment for moderate to severe depression 1. For this patient reporting two weeks of reduced sleep, helplessness, and hopelessness, an SSRI addresses both the depressive episode and comorbid anxiety/panic symptoms.

For PTSD, SSRIs (particularly sertraline and paroxetine) represent first-line pharmacotherapy 4, making them doubly appropriate given this patient's trauma history. The guidelines consistently support SSRIs for anxiety disorders as well 5.

Critical Medication to AVOID

Do not restart or continue benzodiazepines (including clonazepam) in this patient. 2, 3, 6 This is crucial for several reasons:

• The patient overdosed on clonazepam, demonstrating access and misuse risk
• Benzodiazepines are specifically discouraged in borderline personality disorder due to disinhibition risk, potential for dependence, and lack of efficacy for core BPD symptoms 2, 3
• Guidelines recommend benzodiazepines only for very short-term crisis management in depression with severe anxiety/agitation, not for ongoing treatment 5
• The patient already received lorazepam in the ED for acute agitation—this should not continue beyond crisis stabilization 7

Addressing the Stimulant Overdose Component

Discontinue Vyvanse (lisdexamfetamine) indefinitely. 8 The FDA labeling clearly warns that:

• CNS stimulants carry abuse and misuse potential, with risk of overdose and death 8
• Psychiatric adverse reactions including anxiety, agitation, and psychosis can occur 8
• The patient's overdose involving Vyvanse demonstrates either intentional self-harm or misuse

The two-week history of decreased sleep could represent stimulant effects rather than primary insomnia. Reassess ADHD symptoms after mood stabilization—if ADHD treatment is truly needed later, consider non-stimulant alternatives (atomoxetine, guanfacine) given the overdose history.

What NOT to Start Routinely

Avoid routine antipsychotic continuation beyond acute crisis management. The haloperidol given in the ED was appropriate for acute agitation 7, but there is no evidence supporting routine antipsychotic use in BPD 2, 3. While some patients with BPD receive antipsychotics (particularly quetiapine) in clinical practice 6, guidelines emphasize this is off-label without strong evidence for core BPD symptoms 2, 3.

Exception: If psychotic symptoms emerge or persist (assess carefully for trauma-related dissociation versus true psychosis), low-dose quetiapine 25-50 mg at bedtime could address both psychotic symptoms and insomnia 3, but this should be time-limited and reassessed frequently.

Monitoring and Titration Strategy

Following American College of Physicians guidelines 1:

• Week 1-2: Start SSRI at standard initial dose (sertraline 50 mg or escitalopram 10 mg daily)
• Week 2-6: Monitor response weekly initially, then every 2 weeks. Assess for suicidal ideation intensification (FDA black box warning for young adults)
• Week 6-8: If inadequate response (<50% symptom reduction), increase dose (sertraline to 100-150 mg, escitalopram to 20 mg)
• Ongoing: Continue monitoring for 4-9 months after achieving response; given multiple prior episodes, longer maintenance likely needed 1

Addressing Sleep Without Benzodiazepines

For the reported sleep disturbance:

• First-line: Sleep hygiene, stimulus control
• If pharmacotherapy needed: Trazodone 25-50 mg at bedtime (evidence in depression with insomnia) 9 or low-dose mirtazapine 7.5-15 mg (sedating at lower doses)
• Avoid: Benzodiazepines, zolpidem (abuse potential), or continuing stimulants that worsen insomnia

Common Pitfalls to Avoid

1. Polypharmacy trap: BPD patients frequently receive multiple medications (mean 2.8 psychotropics) 6, but guidelines emphasize psychotherapy as primary treatment with minimal, targeted pharmacotherapy 2, 3

2. Benzodiazepine continuation: Despite the overdose, there may be pressure to restart clonazepam for "anxiety"—resist this. SSRIs take 4-8 weeks for full anxiolytic effect; short-term tolerability of anxiety is safer than benzodiazepine dependence risk

3. Mistaking BPD emotional dysregulation for bipolar disorder: The relationship issues and mood instability are consistent with BPD, not necessarily bipolar disorder requiring mood stabilizers

4. Overlooking psychotherapy: Medication is adjunctive—dialectical behavior therapy (DBT) or psychodynamic therapy should be the primary treatment modality 3, 10, 11

Safety Considerations

• Overdose risk assessment: Prescribe limited quantities initially (e.g., 7-14 day supplies)
• Lethal means counseling: SSRIs are safer in overdose than TCAs, but still counsel on medication storage
• Monitor for serotonin syndrome: Given recent cyclobenzaprine (weak serotonergic properties) overdose, though risk is low 8